Literature DB >> 12771272

Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination.

I Pirko1, N L Kuntz, M Patterson, B M Keegan, B G Weinshenker, M Rodriguez.   

Abstract

Reported are three children with MS who responded dramatically to interferon-beta (IFNbeta) therapy. While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration. These cases emphasize two interesting observations: 1) IFNbeta treatment did not prevent development of CIDP; 2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771272     DOI: 10.1212/01.wnl.0000064163.94122.eb

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon beta 1B.

Authors:  Eleonora Cocco; Elena Mamusa; Nicola Carboni; Giovanni Marrosu; Alessandro Vannelli; Maria Giuseppina Mascia; Antonella Sirca; Maria Giovanna Marrosu
Journal:  J Neurol       Date:  2005-06-20       Impact factor: 4.849

2.  Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.

Authors:  Janine Mikolajczak; Hanna Zimmermann; Ahmad Kheirkhah; Ella Maria Kadas; Timm Oberwahrenbrock; Rodrigo Muller; Aiai Ren; Joseph Kuchling; Holger Dietze; Harald Prüss; Friedemann Paul; Pedram Hamrah; Alexander U Brandt
Journal:  Mult Scler       Date:  2016-11-03       Impact factor: 6.312

3.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 4.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

5.  Chronic inflammatory demyelinating polyradiculoneuropathy: A case report.

Authors:  Bolin Hu; Yibiao Zhou; Xiaoqing Lu; Qianqian Xiong; Qing Liu; Xueliang Qi; Weijiang Ding
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica.

Authors:  Yoko Warabi; Mikihiro Yamazaki; Toshio Shimizu; Masahiro Nagao
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

7.  Alterations of peripheral nerve excitability in an experimental autoimmune encephalomyelitis mouse model for multiple sclerosis.

Authors:  Nathalia Bernardes Teixeira; Gisele Picolo; Aline Carolina Giardini; Fawzi Boumezbeur; Géraldine Pottier; Bertrand Kuhnast; Denis Servent; Evelyne Benoit
Journal:  J Neuroinflammation       Date:  2020-09-07       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.